An Opportune Time to Consider Glucose–Insulin–Potassium Therapy for Takotsubo Syndrome

John E. Madias

Research output: Contribution to journalArticlepeer-review

Abstract

This viewpoint takes the position that the management of takotsubo syndrome (TTS) should not wait the elucidation of the pathophysiology of this mysterious malady but should move along the direction currently implemented for acute coronary syndromes (ACS). Accordingly, and since there is a current rekindled interest in the salutary effect of glucose–insulin–potassium (GIK) for the management of acute myocardial infarction, and in general of the broad domain of ACS, it is the opinion of this author that it is an opportune time for the same therapeutic principles, including GIK, applied for the broad domain of suspected ACS (in view of the prospective phase 3 IMMEDIATE-2 trial), to be considered for TTS.

Original languageEnglish
Pages (from-to)467-470
Number of pages4
JournalAmerican Journal of Cardiovascular Drugs
Volume23
Issue number5
DOIs
StatePublished - Sep 2023

Fingerprint

Dive into the research topics of 'An Opportune Time to Consider Glucose–Insulin–Potassium Therapy for Takotsubo Syndrome'. Together they form a unique fingerprint.

Cite this